{
  "trial_id": "NCT02504632",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "transfemoral TAVI with MCV aspirin treatment",
      "label": "met"
    },
    {
      "criterion": "with stable coronary artery disease treated by aspirin but without aortic stenosis.",
      "label": "met"
    },
    {
      "criterion": "Severe symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.",
      "label": "met"
    },
    {
      "criterion": "Aspirin treatment (75-160 mg/d for at least one week)",
      "label": "met"
    },
    {
      "criterion": "Control group",
      "label": "unknown"
    },
    {
      "criterion": "Any co-morbidity limiting life-expectancy < 1 year",
      "label": "not_met"
    },
    {
      "criterion": "Terminal chronic kidney disease requiring hemodialysis thrombocytopenia <100 G/L, anemia (Hb < 10 g/dl)",
      "label": "unknown"
    },
    {
      "criterion": "Treatment by another antiplatelet agent within 10 days before the procedure",
      "label": "not_met"
    }
  ],
  "exclusion": [
    {
      "criterion": "platelet agents other than aspirin",
      "label": "triggers"
    },
    {
      "criterion": "Procedures: Specific platelet activation markers, circulating platelet/monocytes aggregates, platelet reactivity and vWF will be assessed in peripheral venous blood before, 1 and 5 days after TAVI and in ascending aorta during the procedure.",
      "label": "triggers"
    }
  ],
  "notes": "Patient has severe symptomatic AS with aortic valve area < 0.6 cm2/m2 SC, deemed high risk for surgery and suitable for TF TAVI with MCV prosthesis.",
  "_meta": {
    "topic_id": "2",
    "trial_id": "NCT02504632",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}